Arch Esp Urol. 2025 Mar;78(2):164-169. doi: 10.56434/j.arch.esp.urol.20257802.23.
ABSTRACT
OBJECTIVE: This study aimed to investigate the effectiveness, safety and outcomes of the combination therapy of low-intensity extracorporeal shockwave therapy (Li-ESWT) and platelet-rich plasma (PRP) for the treatment of chronic-phase Peyronie’s disease.
METHODS: The clinical outcomes of patients diagnosed with Peyronie’s disease and treated with Li-ESWT combined with PRP at our clinic between January 2018 and January 2024 were retrospectively reviewed and analysed. Twenty-three patients were excluded based on inclusion criteria, leaving 26 patients for the retrospective analysis. Each patient received three sessions of PRP and six sessions of Li-ESWT. The treatment regimen involved sessions administered twice weekly over a period of 3 weeks, followed by 1-week post-treatment follow-up. The patients were then monitored for 24 weeks.
RESULT: After treatment, no significant reduction in average plaque size was observed. However, a statistically significant average improvement of 10° was noted for penile curvature. Among the patients, 14 (53.8%) reported satisfaction with the treatment outcome, and 12 (46.2%) expressed dissatisfaction. No significant adverse effects were observed at the injection sites or in the areas subjected to Li-ESWT post-procedure.
CONCLUSIONS: The combination of Li-ESWT and PRP is effective and safe for the treatment of chronic-phase Peyronie’s disease.
PMID:40191859 | DOI:10.56434/j.arch.esp.urol.20257802.23
